Aortoiliac Occlusive Disease
Aortoiliac occlusive disease framed first as an inflow problem before the device decision: aortic bifurcation, common iliac, external iliac, and iliofemoral inflow placed inside the patient's symptom and risk profile. The chapter frames endovascular, hybrid, and open inflow reconstruction.
Multidisciplinary board: A board-room discussion with roles, escalation triggers, surveillance, patient goals, and what makes the pathway coherent.
Choose the hostsStart with the inflow problem
Aortoiliac occlusive disease is first a problem of inflow. The trainee should begin by deciding whether the aortic bifurcation, common iliac arteries, external iliac arteries, or combined iliofemoral segment is limiting perfusion, and then place that anatomy inside the patient’s clinical presentation rather than treating the angiogram in isolation. Contemporary PAD frameworks explicitly include aortoiliac disease alongside femoropopliteal and infrapopliteal disease, so the first clinical question is not “Can this lesion be crossed?” but “What limb- and patient-level goal requires inflow correction?”
The second step is to separate morphology from indication. TASC II remains useful as a common language because it stratifies aortoiliac lesions by length, laterality, aortic bifurcation involvement, and common or external iliac artery disease. Its historical teaching was that TASC A and most B lesions were usually endovascular lesions, whereas C and D lesions were historically open-surgery territory; modern practice should use that boundary as orientation, not dogma, because later evidence and newer guideline frameworks incorporate endovascular durability, covered stents, calcification, runoff, and patient risk.
The inflow assessment must also identify whether the iliac lesion is isolated or part of multilevel disease. In claudication, an iliac stenosis may explain exertional disability and may be the dominant lesion to treat; in CLTI, the same lesion may be only one component of a limb plan that also requires a target arterial path and reliable distal perfusion. The Global Vascular Guidelines frame CLTI decisions around Patient risk, Limb severity, and ANatomic complexity, with WIfI for limb threat and GLASS for the target artery path and limb-based patency concept; aortoiliac repair is therefore part of the limb strategy, not an isolated technical victory.
A practical bedside rule is to ask whether inflow correction alone can plausibly achieve the clinical goal. For lifestyle-limiting claudication with a clear iliac culprit, isolated iliac treatment may be enough when symptoms persist despite medical therapy and structured exercise. For tissue loss, gangrene, or rest pain, inflow correction is judged by whether it enables wound healing, supports a distal reconstruction, or makes the selected target arterial path adequate.
Claudication and CLTI use different thresholds
For claudication, intervention is elective and goal-bound. The 2024 multisociety PAD guideline places revascularization after guideline-directed therapy and structured exercise have not produced acceptable functional improvement. This means the threshold is persistent, patient-defined disability with anatomy that matches the symptoms, not the mere presence of an iliac stenosis or occlusion.
- US guideline framework for aortoiliac inflow disease and staged claudication care.
- Trigger
- Adults with lower-extremity PAD under US multisociety guideline care.
- Branch / Endpoint
- Do not infer device-specific aortoiliac choices from this general guideline fact.
Citation - The 2024 ACC/AHA multi-society PAD guideline is the current North American framework, organizing recommendations around four clinical presentations and treating aortoiliac intervention as conditional on persistent disability after best medical therapy and exercise for claudication, and as a limb-plan component for CLTI.
- Trigger
- Adults with lower-extremity peripheral artery disease across asymptomatic, claudication, CLTI, and ALI subsets, including aortoiliac inflow disease.
- Branch / Endpoint
- Exact class (I/IIa/IIb/III) and level-of-evidence wording are inside the recommendation table; the source-page summary describes the framework. Use the source table for formal class and level wording.
Citation - Reference point CLTI inflow framing on PLAN + WIfI + GLASS, citing GVG 2019; treat aortoiliac repair as a component of the limb plan rather than an isolated lesion when discussing CLTI.
- Trigger
- Adults with chronic limb-threatening ischemia and inflow or multilevel disease, including aortoiliac segments that affect distal revascularization or wound healing.
- Branch / Endpoint
- Exact percentages for limb-based patency by GLASS stage and the recommendation classes for bypass-first vs endovascular-first under the EBR framework sit inside the full guideline tables — confirm against the open PMC EJVES version or against a visual render of the JVS tables before publishing specific quantitative claims.
Citation - COMPASS PAD supports rivaroxaban 2.5 mg twice daily plus aspirin for chronic, stable PAD; the post-revascularization setting is informed by VOYAGER PAD.
- Trigger
- Adults with stable PAD or carotid disease (or coronary disease with ABI <0.90), including aortoiliac and femoropopliteal patients without recent revascularization.
- Branch / Endpoint
- Major bleeding was mainly gastrointestinal, not fatal or intracranial. This is a subgroup analysis drawn from COMPASS, a broader stable-vascular-disease RCT.
Citation - Frame post-revascularization antithrombotic therapy after aortoiliac and femoropopliteal intervention as a candidate for low-dose rivaroxaban + aspirin per VOYAGER PAD, individualised for bleeding risk.
- Trigger
- Adults with symptomatic PAD who have undergone lower-extremity revascularization (endovascular, surgical, or hybrid), including aortoiliac territory.
- Branch / Endpoint
- Bleeding signal is real (HR ~1.4 for major bleeding); the decision must be individualised against patient bleeding risk, age, renal function, and concomitant therapy. The impact of concomitant clopidogrel was analysed separately (Hiatt et al, Circulation 2020).
Citation
For CLTI, the threshold is lower because the endpoint is limb salvage and wound healing rather than walking distance alone. The decision is still not automatic: the surgeon must stage limb threat, estimate patient risk, and define an anatomic plan that includes documented inflow adequacy before judging any infrainguinal reconstruction as sufficient. Aortoiliac correction may be the first move, a concomitant move, or a prerequisite to a distal bypass or endovascular target artery path.
The distinction matters during consent. In claudication, the patient should understand that best medical therapy and exercise remain foundational, and that the purpose of revascularization is durable symptom relief when disability persists. In CLTI, the conversation should be organized around the limb plan: inflow, runoff, wound severity, patient risk, and the likelihood that additional distal procedures or surveillance-driven reinterventions may be necessary.
Medical therapy is not separate from procedural care. In stable PAD, including patients with aortoiliac and femoropopliteal disease, low-dose rivaroxaban plus aspirin reduced major cardiovascular events and major adverse limb events compared with aspirin alone, but increased major bleeding. After lower-extremity revascularization, VOYAGER PAD similarly showed fewer composite ischemic limb and cardiovascular events with low-dose rivaroxaban plus aspirin, with an increased ISTH major bleeding signal; this is a risk discussion, not a reflex prescription.
Open, endovascular, and hybrid comparisons stay goal-bound
Endovascular treatment is generally favored for short iliac stenoses or occlusions when the clinical indication is sound and the anatomy is suitable. The European guideline framework supports endovascular therapy for short iliac disease, while contemporary PAD guidance emphasizes individualized modality choice based on lesion extent, calcification, runoff, patient risk, and durability needs. The lesson for trainees is to avoid presenting endovascular repair as “lesser surgery”; it is a deliberate reconstruction whose adequacy is measured against the clinical goal.
Hybrid repair is the natural option when inflow disease and common femoral or iliofemoral disease coexist. The 2017 ESC/ESVS framework supports combined iliac and femoral repair for iliofemoral disease, which translates in practice to matching endovascular iliac inflow restoration with open femoral reconstruction when the groin segment is a critical part of the lesion pattern. The operative judgment is not whether one discipline “wins,” but whether the combined repair produces a durable inflow channel and a usable femoral outflow bed.
Open aortobifemoral or related aortic reconstruction remains important for selected fit patients with extensive disease, especially when occlusion reaches toward the renal arteries or when endovascular durability is unlikely to meet the patient’s need. TASC II originally placed extensive C/D disease in the open-preferred category, and modern European guidance continues to keep open reconstruction in the armamentarium while individualizing choice by risk, calcification, runoff, and durability.
For complex bifurcation disease, modern comparison should be framed as open aortobifemoral reconstruction versus endovascular bifurcation reconstruction, not simply surgery versus stenting. Contemporary evidence families include comparisons of open ABF with bifurcation stenting, kissing stents, and covered endovascular reconstruction of the aortic bifurcation, along with CERAB registry and synthesis data. These sources support discussing feasibility and comparative selection, but they do not remove the need to individualize by patient risk, lesion complexity, calcification, runoff, and expected durability.
Device selection is most defensible when tied to lesion complexity. COBEST showed that covered balloon-expandable stents reduced binary restenosis compared with bare-metal stents overall, with the clearest advantage in TASC C/D lesions and no significant difference in TASC B lesions. At 5 years, the durability advantage for covered balloon-expandable stents persisted for TASC C/D disease, while TASC B outcomes remained similar; therefore, extensive aortoiliac disease often justifies covered-stent preference, whereas short focal lesions allow more pragmatic platform selection.
Calcification and special anatomy change the operation
Calcification changes both the technical plan and the threshold for declaring an approach suitable. Contemporary European guidance explicitly includes calcification, lesion extent, runoff, patient risk, and durability needs in modality choice, and that is especially important in aortoiliac disease because the same angiographic occlusion may behave very differently when it is heavily calcified, bifurcation-centered, or associated with poor femoral outflow.
Severe calcification should make the surgeon slow down before choosing access, device type, and reconstruction endpoint. The evidence base supports covered or balloon-expandable stents for complex iliac disease, but it does not justify a one-device-fits-all rule. In practice, the decision should remain anchored to whether the reconstruction can safely create durable inflow across the diseased aortoiliac segment and whether the runoff bed can use that inflow.
Special anatomy may require open creativity rather than routine anatomic reconstruction. A reported case of abdominal aortic aneurysm with bilateral iliac occlusion, severe calcification, and profunda-dependent runoff used open aortic replacement with a three-branched graft to the right internal iliac and both profunda femoris arteries; ankle-brachial indices improved from immeasurable to 0.58 and 0.57, and claudication resolved. This is a useful teaching example of matching reconstruction to available outflow, but it is a single case and should not be generalized into a routine strategy.
Profunda-dependent runoff is a reminder that “iliac repair” may not end at the inguinal ligament. When profunda femoris arteries are the critical outflow bed, the reconstruction must be planned around them, and the surgeon must decide whether an iliac-only approach will be sufficient or whether open femoral or aortoprofunda reconstruction is required. The available support for this point is case-level rather than comparative, so it should guide operative imagination, not dictate standard treatment.
Durability and follow-up complete the decision
The operation is not complete when the iliac segment opens; it is complete when the chosen reconstruction has a realistic surveillance and durability plan. TASC II remains useful for describing morphology, but modern decision-making must revisit its historical open-versus-endovascular boundary using contemporary covered-stent evidence, patient risk, runoff, calcification, and the clinical consequence of failure.
For stented iliac disease, durability expectations should be lesion-specific. COBEST and its 5-year follow-up support covered balloon-expandable stents for extensive TASC C/D aortoiliac lesions, while shorter TASC B lesions showed similar outcomes between covered and bare-metal stents. That distinction is clinically important: complex bifurcation or long occlusive disease requires a stronger durability argument than a focal stenosis treated for claudication.
Follow-up also has to include systemic event prevention. In stable PAD, rivaroxaban 2.5 mg twice daily plus aspirin reduced major cardiovascular and limb events compared with aspirin alone but increased major bleeding. After lower-extremity revascularization, the same low-dose rivaroxaban strategy added to aspirin reduced ischemic limb and cardiovascular events in VOYAGER PAD, again with more major bleeding. The vascular surgeon should therefore document both the ischemic rationale and the bleeding-risk rationale when choosing post-procedure antithrombotic therapy.
Failure modes should be anticipated at the original operation. In claudication, restenosis or occlusion may return the patient to disability and may require reintervention, but the limb is usually not immediately threatened. In CLTI, inflow failure can undermine a distal target arterial path, wound healing, or bypass adequacy; this is why CLTI planning must keep inflow patency tied to the broader PLAN, WIfI, and GLASS framework rather than treating the iliac repair as a separate endpoint.
The trainee’s final synthesis should be explicit: define the indication, name the aortoiliac morphology, state whether disease is isolated or multilevel, choose endovascular, hybrid, or open repair according to goal and risk, justify device strategy when stenting is used, and prescribe follow-up that addresses both reconstruction durability and cardiovascular protection. This keeps treatment of aortoiliac occlusive disease aligned with modern PAD and CLTI frameworks while preserving the central surgical principle: durable inflow must serve the patient’s limb-level goal.
References
- 1.2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the management of lower extremity peripheral artery disease. Circulation. 2024.PubMed-indexed articleClinical practice guideline2024
2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the management of lower extremity peripheral artery disease. Circulation. 2024. doi:10.1161/CIR.0000000000001251. PMID:38743805.
- 2.
- 3.
- 4.
- 5.ABF vs aortoiliac stenting with bifurcation reconstruction for TASC II D AIOD. Ann Vasc Surg. 2022;81:240-247.PubMed-indexed articleRegistry / cohort2022
Comparison of Aortobifemoral Bypass to Aortoiliac Stenting with Bifurcation Reconstruction for TASC II D Aortoiliac Occlusive Disease. Ann Vasc Surg. 2022;81:240-247. PMID 34788703. DOI 10.1016/j.avsg.2021.10.040
- 6.Aortobifemoral bypass vs covered endovascular reconstruction of the aortic bifurcation. J Vasc Surg. 2024.PubMed-indexed articleRegistry / cohort2024
Aortobifemoral bypass vs covered endovascular reconstruction of the aortic bifurcation. J Vasc Surg. 2024. doi:10.1016/j.jvs.2024.03.437. PMID:38565344.
- 7.Indes JE, et al. ABF vs aortoiliac kissing stents in complex AIOD. J Vasc Surg. 2017;65(1):82-89.PubMed-indexed articleRegistry / cohort2017
A comparison between aortobifemoral bypass and aortoiliac kissing stents in patients with complex aortoiliac obstructive disease. J Vasc Surg. 2017;65(1):82-89. PMID 27633164. DOI 10.1016/j.jvs.2016.06.107
- 8.Aortoprofunda and internal iliac bypass in open repair of abdominal aortic aneurysm with aortoiliac occlusive disease. J Surg Case Rep. 2026.DOI publisher routeCase report2026
Aortoprofunda and internal iliac bypass in open repair of abdominal aortic aneurysm with aortoiliac occlusive disease. J Surg Case Rep. 2026. doi:10.1093/jscr/rjaf1020.
- 9.2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed b. Eur Heart J. 2018.DOI publisher routeClinical practice guideline2017
2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed b. Eur Heart J. 2018. doi:10.1093/eurheartj/ehx095.
- 10.
- 11.
- 12.
- 13.Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007.DOI publisher routeClinical practice guideline2007
Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007. doi:10.1016/j.jvs.2006.12.037.
- 14.
Educational use only
AI assists this editorial workflow. Published updates are human-reviewed before publication.
Not intended to diagnose, monitor, predict, prognose, treat, or alleviate disease.
Verify clinically relevant information against primary sources and current guidelines.